Literature DB >> 7479553

Interaction between bile salts and beta-adrenoceptor antagonists.

M P Grosvenor1, J E Löfroth.   

Abstract

The interactions between beta-adrenoceptor antagonists and bile salts were investigated by microcalorimetry. Nadolol and oxprenolol interactions with dihydroxy salts could be described by a 1:1 interaction model with the thermodynamic parameters indicating that the drugs were incorporated within the bile salt aggregates. This weak interaction was primarily hydrophobic although electrostatic attraction also played a role. Atenolol and metoprolol did not interact with the dihydroxy salts. None of the compounds interacted with trihydroxy bile salts or with salts below their aggregation concentration. Phase separation resulted when propranolol and alprenolol were present in dihydroxy salt solutions above a certain concentration with the interaction being of a hydrophobic and electrostatic nature. The implications of these results on in-vivo drug absorption are discussed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7479553     DOI: 10.1023/a:1016203424278

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  11 in total

1.  The surface activity and self-association of some beta-adrenoceptor blocking agents in aqueous solution.

Authors:  D Attwood; S P Agarwal
Journal:  J Pharm Pharmacol       Date:  1979-06       Impact factor: 3.765

Review 2.  Enthalpy-entropy compensation phenomena in water solutions of proteins and small molecules: a ubiquitous property of water.

Authors:  R Lumry; S Rajender
Journal:  Biopolymers       Date:  1970       Impact factor: 2.505

Review 3.  Mechanisms of surfactant effects on drug absorption.

Authors:  M Gibaldi; S Feldman
Journal:  J Pharm Sci       Date:  1970-05       Impact factor: 3.534

4.  Effect of neomycin and kanamycin upon intestinal absortion.

Authors:  W W Faloon; I C Paes; D Woolfolk; H Nankin; K Wallace; E N Haro
Journal:  Ann N Y Acad Sci       Date:  1966-06-14       Impact factor: 5.691

5.  Intestinal absorption of a beta-adrenergic blocking agent nadolol. I. Comparison of absorption behavior of nadolol with those of other beta-blocking agents in rats.

Authors:  T Yamaguchi; C Ikeda; Y Sekine
Journal:  Chem Pharm Bull (Tokyo)       Date:  1986-08       Impact factor: 1.645

6.  Proceedings: An investigation of the properties of propranolol hydrochloride in aqueous solution.

Authors:  D N Elliott; P H Elworthy; D Attwood
Journal:  J Pharm Pharmacol       Date:  1973-12       Impact factor: 3.765

7.  Rate of dissolution of griseofulvin and hexoestrol in bile salt solutions.

Authors:  T R Bates; M Gibaldi; J L Kanig
Journal:  Nature       Date:  1966-06-25       Impact factor: 49.962

8.  The influence of bile salts on the absorption in vitro and in vivo of propranolol.

Authors:  M R Gasco; M Trotta; M Eandi
Journal:  J Pharm Biomed Anal       Date:  1984       Impact factor: 3.935

9.  Differences in effects on drug absorption between dihydroxy and trihydroxy bile salts.

Authors:  T Kimura; K Inui; H Sezaki
Journal:  J Pharmacobiodyn       Date:  1985-07

10.  Intestinal absorption of drugs. III. The influence of taurocholate on the disappearance kinetics of hydrophilic and lipophilic drugs from the small intestine of the rat.

Authors:  F G Poelma; R Breäs; J J Tukker
Journal:  Pharm Res       Date:  1990-04       Impact factor: 4.200

View more
  3 in total

Review 1.  Multiple peaking phenomena in pharmacokinetic disposition.

Authors:  Neal M Davies; Jody K Takemoto; Dion R Brocks; Jaime A Yáñez
Journal:  Clin Pharmacokinet       Date:  2010-06       Impact factor: 6.447

2.  Predicting pharmacokinetic food effects using biorelevant solubility media and physiologically based modelling.

Authors:  Hannah M Jones; Neil Parrott; Gerd Ohlenbusch; Thierry Lavé
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

3.  Meal composition effects on the oral bioavailability of indinavir in HIV-infected patients.

Authors:  P L Carver; D Fleisher; S Y Zhou; D Kaul; P Kazanjian; C Li
Journal:  Pharm Res       Date:  1999-05       Impact factor: 4.200

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.